Triptans other than sumatriptan in child and adolescent migraine: literature review

References

• Abu-Arefeh I, Russell G. Prevalence of headache and migraine in schoolchildren. BMJ309, 765–769 (1994).
   PubMed Web of Science ®Google Scholar
• Mortimer MJ, Kay J, Jaron A. Childhood migraine in general practice: clinical features and characteristics. Cephalalgia12, 238–243 (1992).
   PubMed Web of Science ®Google Scholar
• Barea LM, Tannhauser M, Rotta NT. An epidemiologic study of headache among children and adolescents of southern Brazil. Cephalalgia16, 545–549 (1996).
   PubMed Web of Science ®Google Scholar
• Metsähonkala L, Sillanpää M, Tuominen J. Use of health care services in childhood migraine. Headache36, 423–428 (1996).
   PubMed Web of Science ®Google Scholar
• Winner P, Wasiewski W, Gladstein J, Linder S. Multicenter prospective evaluation of proposed pediatric migraine revisions to the IHS criteria. Pediatric Headache Committee of the American Association for the Study of Headache. Headache37, 545–548 (1997).
   PubMed Web of Science ®Google Scholar
• Degrauw TJ, Hershey AD, Powers SW, Bentti AL. Diagnosis of migraine in children attending a pediatric headache clinic. Headache39, 481–485 (1999).
   PubMed Web of Science ®Google Scholar
• Headache Classification Subcommittee of the International Headache Society. The international classification of headache disorders. Cephalalgia24(Suppl. 1), 24–36 (2004).
   PubMed Web of Science ®Google Scholar
• Headache Classification Committee of the International Headache Society. Classification and diagnostic criteria for headache disorders, cranial neuralgias and facial pain. Cephalalgia8(Suppl. 7), 1–96 (1988).
   Web of Science ®Google Scholar
• Landy S. Migraine throughout the life cycle: treatment through the ages. Neurology62(Suppl. 2), S2–S8 (2004).
   Google Scholar
• Ferrari MD, Roon KI, Lipton RB, Goadsby PJ. Oral triptans (serotonin, 5-HT1B/1D agonists) in acute migraine treatment – a meta-analysis of 53 trials. Lancet358, 1668–1675 (2001).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ, Lipton RB, Ferrari MD. Migraine – current understanding and treatment. N. Engl. J. Med.346, 257–270 (2002).
   PubMed Web of Science ®Google Scholar
• Dowson AJ, Mathew NT, Pascual J. Review of clinical trials using early acute intervention with oral triptans for migraine management. Int. J. Clin. Pract.60, 698–706 (2006).
   PubMed Web of Science ®Google Scholar
• Evers S, Afra J, Frese A et al.; European Federation of Neurological Societies. EFNS guideline on the drug treatment of migraine – revised report of an EFNS task force. Eur. J. Neurol.16, 968–981 (2009).
   PubMed Web of Science ®Google Scholar
• Johnston MM, Rapoport AM. Triptans for the management of migraine. Drugs70, 1505–1518 (2010).
   PubMed Web of Science ®Google Scholar
• Goadsby PJ. Serotonin receptor ligands: treatments of acute migraine and cluster headache. Handb. Exp. Pharmacol.177, 129–143 (2007).
   Google Scholar
• Bulloch B, Tenenbein M. Emergency department management of pediatric migraine. Pediatr. Emerg. Care16, 196–201 (2000).
   PubMed Web of Science ®Google Scholar
• Hamalainen ML, Hoppu K, Santavuori P. Sumatriptan for migraine attacks in children: a randomized placebo-controlled study. Do children with migraine respond to oral sumatriptan differently from adults? Neurology48, 1100–1103 (1997).
   PubMed Web of Science ®Google Scholar
• Winner P, Rothner AD, Saper J et al. A randomized, double-blind, placebo-controlled study of sumatriptan nasal spray in the treatment of acute migraine in adolescents. Pediatrics106, 989–997 (2000).
   PubMed Web of Science ®Google Scholar
• Winner P, Rothner AD, Wooten JD, Webster C, Ames M. Sumatriptan nasal spray in adolescent migraineurs: a randomized, double-blind, placebo-controlled, acute study. Headache46, 212–222 (2006).
   PubMed Web of Science ®Google Scholar
• Ahonen K, Hamalainen ML, Rantala H, Hoppu K. Nasal sumatriptan is effective in treatment of migraine attacks in children: a randomized trial. Neurology62, 883–887 (2004).
   PubMed Web of Science ®Google Scholar
• Ueberall MA, Wenzel D. Intranasal sumatriptan for the acute treatment of migraine in children. Neurology52, 1507–1510 (1999).
   PubMed Web of Science ®Google Scholar
• Hershey AD, Powers SW, LeCates S, Bentti AL. Effectiveness of nasal sumatriptan in 5- to 12-year-old children. Headache41, 693–697 (2001).
   PubMed Web of Science ®Google Scholar
• Rothner AD, Winner P, Nett R et al. One-year tolerability and efficacy of sumatriptan nasal spray in adolescents with migraine: results of a multicenter, open-label study. Clin. Ther.22, 1533–1546 (2000).
   PubMed Web of Science ®Google Scholar
• Natarajan S, Jabbour JT, Webster CJ, Richardson MS. Longterm tolerability of sumatriptan nasal spray in adolescent patients with migraine. Headache44, 969–977 (2004).
   PubMed Web of Science ®Google Scholar
• Pakalnis A, Kring D, Paolicchi J. Parental satisfaction with sumatriptan nasal spray in childhood migraine. J. Child Neurol.18, 772–775 (2003).
   PubMed Web of Science ®Google Scholar
• Linder SL. Subcutaneous sumatriptan in the clinical setting: the first 50 consecutive patients with acute migraine in a pediatric neurology office practise. Headache36, 419–422 (1996).
   PubMed Web of Science ®Google Scholar
• MacDonald JT. Treatment of juvenile migraine with subcutaneous sumatriptan. Headache34, 581–582 (1994).
   PubMed Web of Science ®Google Scholar
• Loder E, Goldstein R, Biondi D. Placebo effects in oral triptan trials: the scientific and ethical rational for continued use of placebo controls. Cephalalgia25, 124–131 (2005).
   PubMed Web of Science ®Google Scholar
• Fernandes R, Ferreira JJ, Sampaio C. The placebo response in studies of acute migraine. J. Pediatr.152, 527–533 (2008).
   PubMed Web of Science ®Google Scholar
• McAlhany A. Efficacy of sumatriptan in the treatment of migraine: a review of the literature. J. Neurosci. Nurs.33, 270–277, 285 (2001).
   PubMedGoogle Scholar
• Hämäläinen M, Jones M, Loftus J, Saiers J. Sumatriptan nasal spray for migraine: a review of studies in patients aged 17 years and younger. Int. J. Clin. Pract.56, 704–709 (2002).
   PubMed Web of Science ®Google Scholar
• Major PW, Grubisa HS, Thie NM. Triptans for treatment of acute pediatric migraine: a systematic literature review. Pediatr. Neurol.29, 425–429 (2003).
   PubMed Web of Science ®Google Scholar
• Lewis DW, Winner P, Hershey AD, Wasiewski WW; Adolescent Migraine Steering Committee. Efficacy of zolmitriptan nasal spray in adolescent migraine. Pediatrics120, 390–396 (2007).
   PubMed Web of Science ®Google Scholar
• Evers S, Rahmann A, Kraemer C et al. Treatment of childhood migraine attacks with oral zolmitriptan and ibuprofen. Neurology67, 497–499 (2006).
   PubMed Web of Science ®Google Scholar
• Rothner AD, Wasiewski W, Winner P, Lewis D, Stankowski J. Zolmitriptan oral tablet in migraine treatment: high placebo response in adolescents. Headache46, 101–109 (2006).
   PubMed Web of Science ®Google Scholar
• Edmeads JG, Millson DS. Tolerability profile of zolmitriptan (Zomig; 311C90), a novel dual central and peripherally acting 5HT1B/1D agonist. International clinical experience based on >3000 subjects treated with zolmitriptan. Cephalalgia17(Suppl. 18), 41–52 (1997).
   PubMed Web of Science ®Google Scholar
• Linder SL, Dowson AJ. Zolmitriptan provides effective migraine relief in adolescents. Int. J. Clin. Pract.54, 466–469 (2000).
   PubMed Web of Science ®Google Scholar
• Winner P, Lewis D, Visser WH, Jiang K, Ahrens S, Evans JK. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: a randomized, double-blind, placebo-controlled study. Headache42, 49–55 (2002).
   PubMed Web of Science ®Google Scholar
• Visser WH, Winner P, Strohmaier K et al.; Rizatriptan Protocol 059 and 061 Study Groups. Rizatriptan 5 mg for the acute treatment of migraine in adolescents: results from a double-blind, single-attack study and two open-label, multiple-attack studies. Headache44, 891–899 (2004).
   PubMed Web of Science ®Google Scholar
• Ahonen K, Hämäläinen ML, Eerola M, Hoppu K. A randomized trial of rizatriptan in migraine attacks in children. Neurology67, 1135–1140 (2006).
   PubMed Web of Science ®Google Scholar
• Charles JA. Almotriptan in the acute treatment of migraine in patients 11–17 years old: an open-label pilot study of efficacy and safety. J. Headache Pain7, 95–97 (2006).
   PubMedGoogle Scholar
• Linder SL, Mathew NT, Cady RK, Finlayson G, Ishkanian G, Lewis DW. Efficacy and tolerability of almotriptan in adolescents: a randomized, double-blind, placebo-controlled trial. Headache48, 1326–1336 (2008).
   PubMed Web of Science ®Google Scholar
• Winner P, Linder SL, Lipton RB, Almas M, Parsons B, Pitman V. Eletriptan for the acute treatment of migraine in adolescents: results of a double-blind, placebo-controlled trial. Headache47, 511–518 (2007).
   PubMed Web of Science ®Google Scholar
• Christensen ML, Eades SK, Fuseau E, Kempsford RD, Phelps SJ, Hak LJ. Pharmacokinetics of naratriptan in adolescent subjects with a history of migraine. J. Clin. Pharmacol.41, 170–175 (2001).
   PubMed Web of Science ®Google Scholar
• Elkind AH, Wade A, Ishkanian G. Pharmacokinetics of frovatriptan in adolescent migraineurs. J. Clin. Pharmacol.44, 1158–1165 (2004).
   PubMed Web of Science ®Google Scholar
• Rothner A, Edwards K, Kerr L, DeBussey S, Asgharnejhad M. Efficacy and safety of naratriptan tablets in adolescent migraine. J. Neurol. Sci.150(Suppl. 1), S106 (1997).
   Google Scholar
• Winner P, Powers SW, Kabbouche MA, Hershey AD. Diagnosing and managing headache in children. Curr. Treat. Options Neurol.9, 3–13 (2007).
   PubMedGoogle Scholar
• Vollono C, Capuano A, Mei D et al. Multiple attack study on the available triptans in Italy versus placebo. Eur. J. Neurol.12, 557–563 (2004).
   Web of Science ®Google Scholar